Furthermore, the results of molecular docking revealed that the compound displayed good binding energies, with a shorter binding distance needed when in complex with BIRC5/HIF1α/FLT4 genes, suggesting that it could be a potential inhibitor of this signaling pathway in NSCLC. The gene discussed is BIRC5; the disease is non-small cell lung carcinoma.